625 results on '"Yip, Terry Cheuk-Fung"'
Search Results
2. Alcohol-associated hepatitis trends before and following the onset of the COVID-19 pandemic across two distinct cohorts in the United States and Hong Kong
3. Point-of-Care Noninvasive Prediction of Liver-Related Events in Patients With Nonalcoholic Fatty Liver Disease
4. Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B
5. A Liver Stiffness–Based Etiology-Independent Machine Learning Algorithm to Predict Hepatocellular Carcinoma
6. acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter Study
7. Baseline Viral Load and On-treatment Hepatocellular Carcinoma Risk in Chronic Hepatitis B: A Multinational Cohort Study
8. A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B
9. aMAP Score and Its Combination With Liver Stiffness Measurement Accurately Assess Liver Fibrosis in Chronic Hepatitis B Patients
10. Diabetes Mellitus Impacts on the Performance of Hepatocellular Carcinoma Risk Scores in Chronic Hepatitis B Patients
11. Baveno VII criteria for recompensation predict transplant-free survival in patients with hepatitis B-related decompensated cirrhosis
12. Advanced liver fibrosis predicts heart failure and hospitalizations in people with type 2 diabetes: A prospective cohort study from Hong Kong Diabetes Register
13. Nonalcoholic Fatty Liver Disease: A Unique Entity or Part of the Metabolic Syndrome or Both
14. Drug–drug interactions between direct-acting antivirals and co-medications: a territory-wide cohort study
15. Risk of HCC in Patients with HBV, Role of Antiviral Treatment
16. Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis
17. Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss
18. Minimal Risk of Drug-Induced Liver Injury With Molnupiravir and Ritonavir-Boosted Nirmatrelvir
19. Management of hepatitis B virus reactivation due to treatment of COVID-19
20. Dynamic Changes in ELF Score Predict Hepatocellular Carcinoma in Chronic Hepatitis B Patients Receiving Antiviral Treatment.
21. Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease.
22. Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis
23. Asian perspective on NAFLD-associated HCC
24. Methodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments
25. GS-004 Prognostic significance of a change in liver stiffness measurement by vibration-controlled transient elastography-a multicenter cohort study of 10, 920 patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
26. FRI-387 Similarly low risk of hepatocellular carcinoma and cirrhotic complications in patients in the HBeAg-negative indeterminate phase compared with chronic infection
27. LBP-014 Enhancing prediction of moderate fibrosis in MASLD patients for Resmetirom treatment via machine learning
28. OS-054 Validation of the Baveno VII ‘rule of 5’ in a real-life multicentre cohort of patients with metabolic dysfunction associated steatotic liver disease
29. FRI-239 An inference model of risk factors for liver-related complications among patients with type 2 diabetes mellitus
30. WED-198 Novel deep learning models utilising domain adaptation outperform conventional statistical models for predicting the risk of liver-related complications in patients with metabolic dysfunction-associated steatotic liver disease
31. SAT-292 Coinfection with viral hepatitis increases the short-term but not the long-term risks of hepatocellular carcinoma and hepatic events in adults with alcohol-related cirrhosis
32. FRI-227 Impact of antidiabetic medications on adverse liver outcomes in patients with type 2 diabetes mellitus: independent and interactive effects
33. Hepatocellular carcinoma surveillance after HBsAg seroclearance
34. Unlocking the future: machine learning sheds light on prognostication for early-stage hepatocellular carcinoma
35. Temporal Matrix Completion with Locally Linear Latent Factors for Medical Applications
36. Hepatic Decompensation in Cirrhotic Patients Receiving Antiviral Therapy for Chronic Hepatitis B
37. Predictors of Severe COVID-19 in Patients With Diabetes: A Multicenter Review
38. Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B
39. Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-positive patients.
40. Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC
41. Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B
42. Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure
43. Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China
44. Serum PRO‐C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort
45. CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance
46. Reply to Allaire, M.; Thabut, D. Comment on “Wu et al. Baveno VII Criteria Is an Accurate Risk Stratification Tool to Predict High-Risk Varices Requiring Intervention and Hepatic Events in Patients with Advanced Hepatocellular Carcinoma. Cancers 2023, 15, 2480”
47. Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same?
48. Assessment of HCC Risk in Patients with Chronic HBV (REACH, PAGE-B, and Beyond)
49. Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients
50. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.